Evidence map›Paper›PMID 25646564›Full record

ArticleACS chemical biology2015

Human phospholipase D activity transiently regulates pyrimidine biosynthesis in malignant gliomas.

Thomas P Mathews, Salisha Hill, Kristie L Rose, Pavlina T Ivanova, Craig W Lindsley, H Alex Brown

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS chemical biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Metabolomics of Glioma.Advances in experimental medicine and biology · 2021
    Article
  9. Article
  10. Article
  11. Review
  12. Inhibition of phospholipaseD2 increases hypoxia-induced human colon cancer cell apoptosis through inactivating of the PI3K/AKT signaling pathway.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Thomas P Mathews†Department of Pharmacology and The Vanderbilt Ingram Cancer Center, ‡The Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, §Department of Chemistry, ∥The Vanderbilt Institute of Chemical Biology, ⊥The Vanderbilt Mass Spectrometry Research Center, and #Department of Biochemistry, Vanderbilt University, Nashville, Tennessee 37232, United States.
Salisha Hill†Department of Pharmacology and The Vanderbilt Ingram Cancer Center, ‡The Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, §Department of Chemistry, ∥The Vanderbilt Institute of Chemical Biology, ⊥The Vanderbilt Mass Spectrometry Research Center, and #Department of Biochemistry, Vanderbilt University, Nashville, Tennessee 37232, United States.
Kristie L Rose†Department of Pharmacology and The Vanderbilt Ingram Cancer Center, ‡The Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, §Department of Chemistry, ∥The Vanderbilt Institute of Chemical Biology, ⊥The Vanderbilt Mass Spectrometry Research Center, and #Department of Biochemistry, Vanderbilt University, Nashville, Tennessee 37232, United States.
Pavlina T Ivanova†Department of Pharmacology and The Vanderbilt Ingram Cancer Center, ‡The Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, §Department of Chemistry, ∥The Vanderbilt Institute of Chemical Biology, ⊥The Vanderbilt Mass Spectrometry Research Center, and #Department of Biochemistry, Vanderbilt University, Nashville, Tennessee 37232, United States.
Craig W Lindsley†Department of Pharmacology and The Vanderbilt Ingram Cancer Center, ‡The Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, §Department of Chemistry, ∥The Vanderbilt Institute of Chemical Biology, ⊥The Vanderbilt Mass Spectrometry Research Center, and #Department of Biochemistry, Vanderbilt University, Nashville, Tennessee 37232, United States.
H Alex Brown†Department of Pharmacology and The Vanderbilt Ingram Cancer Center, ‡The Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University Medical Center, §Department of Chemistry, ∥The Vanderbilt Institute of Chemical Biology, ⊥The Vanderbilt Mass Spectrometry Research Center, and #Department of Biochemistry, Vanderbilt University, Nashville, Tennessee 37232, United States.
Vanderbilt University Medical Center · US

Funding

STEROL LIPIDSU54GM069338 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DENNIS, EDWARD A · 2003 to 2013
$72.2M
The Vanderbilt Specialized Chemistry Center for Accelerated Probe DevelopmentU54MH084659 · NIMH · VANDERBILT UNIVERSITY · PI MEILER, JENS · 2008 to 2013
$24.1M
Protein Adducts and Proteome Profiles in Oxidative StressP01ES013125 · NIEHS · VANDERBILT UNIVERSITY · PI PORTER, NED ALLEN · 2005 to 2012
$12.6M
Postdoctoral Training in CNS Drug Discovery ResearchT32MH093366 · NIMH · VANDERBILT UNIVERSITY · PI CONN, P JEFFREY · 2011 to 2015
$1.0M
Receptor-mediated signaling pathways leading to phosphatidic acid generationR01GM121629 · NIGMS · VANDERBILT UNIVERSITY · PI BRASH, ALAN R. · 2017 to 2017
$286k
NIEHS NIH HHS P01 ES013125NIEHS NIH HHS P01-ES013125NIGMS NIH HHS U54 GM069338NIMH NIH HHS 1U54MH084659NIMH NIH HHS 5T32MH93366-02NIMH NIH HHS T32 MH093366NIMH NIH HHS U54 MH084659PHS HHS U54 069338
6 · The paper itself

Abstract

Cancer cells reorganize their metabolic pathways to fuel demanding rates of proliferation. Oftentimes, these metabolic phenotypes lie downstream of prominent oncogenes. The lipid signaling molecule phosphatidic acid (PtdOH), which is produced by the hydrolytic enzyme phospholipase D (PLD), has been identified as a critical regulatory molecule for oncogenic signaling in many cancers. In an effort to identify novel regulatory mechanisms for PtdOH, we screened various cancer cell lines, assessing whether treatment of cancer models with PLD inhibitors altered production of intracellular metabolites. Preliminary findings lead us to focus on how deoxyribonucleoside triphosphates (dNTPs) are altered upon PLD inhibitor treatment in gliomas. Using a combination of proteomics and small molecule intracellular metabolomics, we show herein that PtdOH acutely regulates the production of these pyrimidine metabolites through activation of CAD via mTOR signaling pathways independently of Akt. These changes are responsible for decreases in dNTP production after PLD inhibitor treatment. Our data identify a novel regulatory role for PLD activity in specific cancer types.

Indexed as

Amino Acid SequenceBrain NeoplasmsCell Line, TumorEnzyme InhibitorsGliomaHumansMolecular Sequence DataPhospholipase DPyrimidinesSignal TransductionStructure-Activity RelationshipTOR Serine-Threonine KinasesEnzyme InhibitorsMTOR protein, humanPhospholipase DPyrimidinesTOR Serine-Threonine Kinases

Identifiers

PMID25646564
PMCPMC4433586
OpenAlexW2329911925

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.